|
15 July 2005
Auckland, New Zealand, 15 July 2005 – Genesis Research and Development Corporation Ltd (NZSX/ASX: GEN) advises that Joachim (Aki) von Roy has been elected Chairman of the Board of Directors. At the recent annual meeting of shareholders, Mr von Roy and Dr Stewart Washer (Australia) were elected to the board. Other members of the board are Dr Steve Gillis (USA), Mr Jim McLean and Dr Jim Watson. Mr von Roy commented “Genesis has been through a difficult time but I have every confidence that our current research and development projects can lead to a positive commercial reality. The focus on RNAi therapeutics for the treatment of atopic dermatitis and asthma is a cutting edge concept for dealing with these diseases, and we have the team to become a commercially successful company. The appointment of Dr Stewart Washer to the Board will help us sharpen our understanding of the agri-biotech potential of the company as well as increase our ability to develop collaborations in New Zealand and Australia.” About Genesis Founded in 1994, Genesis is a New Zealand-based biotechnology company. It has built a broad therapeutic development platform targeting immune disorders and cancer and is focusing on developing RNAi therapeutics. The company has an extensive patent portfolio. For more information, please visit www.genesis.co.nz and www.agrigenesis.co.nz Media contacts: Stephen Hall, Chief Executive - Genesis Research and Development Corporation Limited, +64 9 373 5600 Aki von Roy, Chairman- Genesis Research and Development Corporation Limited, +64 21 133 1076 |